taste and excipients identical to verum

DRUG7 trials

Sponsors

ROXALL Medizin GmbH, ROXALL Medizin GmbH, ROXALL Medizin GmbH

Conditions

2008)2008) guidelineBousquet et al.Moderate-to-severe allergic rhinitis / rhino-conjunctivitis due to house dust mites (HDM) for at least one year according to the "Allergic Rhinitis and its Impact on Asthma" (ARIAModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinePatients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (Bousquet et al.

Phase 2

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy

CompletedCTIS2023-505567-37-00

ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2023-08-22End: 2024-10-11Target: 30Updated: 2023-08-22

Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy

CompletedCTIS2023-505880-35-00

ROXALL Medizin GmbH, ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2023-11-10End: 2024-11-07Target: 30Updated: 2023-11-15

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen allergy

CompletedCTIS2024-511383-88-00

ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2024-09-01End: 2025-10-14Target: 50Updated: 2024-07-11

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy

Active, not recruitingCTIS2024-517014-15-00

ROXALL Medizin GmbH2008) guideline, Bousquet et al., Moderate-to-severe allergic rhinitis / rhino-conjunctivitis due to house dust mites (HDM) for at least one year according to the "Allergic Rhinitis and its Impact on Asthma" (ARIA

Start: 2025-05-07Target: 60Updated: 2025-07-16

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy

Active, not recruitingCTIS2024-517515-75-00

ROXALL Medizin GmbH2008), Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (Bousquet et al.

Start: 2025-07-17Target: 40Updated: 2025-04-11

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy

Not yet recruitingCTIS2024-517520-19-00

ROXALL Medizin GmbH2008), Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (Bousquet et al.

Target: 30Updated: 2025-05-27

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy

Active, not recruitingCTIS2024-517521-25-00

ROXALL Medizin GmbH2008), Patients with moderate-to-severe allergic rhinitis/rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (Bousquet et al.

Start: 2025-10-20Target: 30Updated: 2025-08-18